Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals, Inc. director Sheila Gujrathi reported acquiring Series A Non-Voting Convertible Preferred Stock on July 28, 2026, in connection with the acquisition of Vidya Therapeutics, Inc. She received 70,811.877 Series A Preferred shares held directly.
An additional 12,311.279 Series A Preferred shares are held indirectly by SilverArc Private Fund I, L.P., an investment fund with which she is associated; she disclaims beneficial ownership except for any pecuniary interest. The Series A Preferred has no expiration and, subject to conditions, each share is convertible into 1,000 shares of Processa common stock.
Processa Pharmaceuticals, Inc. director Sheila Gujrathi has submitted an initial Form 3 insider ownership report. The statement does not list any reportable holdings of Processa Pharmaceuticals securities or derivative instruments for her and shows no insider transactions at the time covered.
Processa Pharmaceuticals completed the stock-for-stock acquisition of Vidya Therapeutics, making Vidya a wholly owned subsidiary through a two-step merger intended to qualify as a tax-free reorganization. Vidya holders received 558,398 Processa common shares and 142,744.100 shares of Series A Non-Voting Convertible Preferred Stock, each convertible into 1,000 common shares after stockholder approval, subject to beneficial ownership limits.
Processa also entered into a Securities Purchase Agreement for 163,774.679 Series A preferred shares (the PIPE Securities) for approximately $200.0 million in cash, with closing expected July 30, 2026. After the Merger and Financing, on a fully diluted basis, pre-transaction Processa stockholders are expected to hold about 0.9% of common stock, former Vidya equityholders about 46%, and PIPE investors about 52.6%. Certain officers, directors and key holders entered 180-day lock-ups, and the company must file resale registration statements within set deadlines.
Separately, Processa terminated its Elion Oncology license for PCS6422 via a settlement, returning the program to Elion, paying $650,000, and granting Elion a 7.5% non-voting interest in any qualifying NewCo formed within 365 days. The company plans to focus on VT-7208 and continue legacy programs PCS499 and PCS12852, and appointed Vidya founder Sheila Gujrathi, M.D., to its board.
Processa Pharmaceuticals, Inc. director Justin W. Yorke received a grant of 33,500 Restricted Stock Units (RSUs) on July 26, 2026. Each RSU represents a contingent right to one share of common stock and vested upon grant, with distribution deferred until the earlier of termination, six months after grant, a change of control, or death. Following this grant, he holds 38,749 RSUs, stock options for 12,000 shares at an exercise price of $4.96, and common stock totaling 353 shares directly plus additional indirect holdings, all reflecting a 1-for-25 reverse stock split effected on December 17, 2025.
Processa Pharmaceuticals, Inc. reported that Chief Financial Officer Russell Skibsted received a grant of 11,883 Restricted Stock Units on July 26, 2026. These RSUs vested immediately but will be settled later under specified conditions. After the grant he directly holds 17,323 RSUs, 16,689 common shares and stock options over 12,960 shares at a $4.9600 exercise price.
Processa Pharmaceuticals director Geraldine Pannu received a grant of 33,500 Restricted Stock Units on July 26, 2026. Each RSU equals one share of common stock, vested upon grant, and will be settled at the earlier of termination, six months after grant, change of control, or death.
After this award she reports direct holdings of 38,749 RSUs, stock options for 12,000 shares at an exercise price of $4.9600, and 2,391 common shares. Reported amounts reflect the company’s 1-for-25 reverse stock split effective December 17, 2025.
Processa Pharmaceuticals, Inc. granted Chief Executive Officer George K. Ng 9,384 Restricted Stock Units on July 26, 2026. Each RSU equals one common share, vested immediately, with settlement deferred until termination, six months after grant, a change of control, or death.
After this award, Ng directly holds 21,224 RSUs, stock options for 30,720 shares at an exercise price of $4.96 per share, and additional direct and indirect common stock holdings; all reported share amounts reflect a 1-for-25 reverse stock split effected on December 17, 2025.
Neal James R reported acquisition or exercise transactions in this Form 4 filing.
Processa Pharmaceuticals, Inc. director Neal James R received a grant of 62,221 Restricted Stock Units (RSUs) on July 26, 2026, each representing one share of common stock. The RSUs vested upon grant but will be distributed only upon termination, six months after grant, a change of control, or death. Following this award, he holds 67,470 RSUs, stock options for 12,000 shares at $4.96 vesting over three years, and 1,021 common shares, all on a direct-ownership basis. Reported amounts reflect a 1-for-25 reverse stock split effective December 17, 2025.
Processa Pharmaceuticals, Inc. officer Patrick Lin received a grant of 8,450 Restricted Stock Units on 2026-07-26. Each RSU equals one share of common stock, vesting upon grant but distributed only at the earlier of termination, six months after grant, a change of control, or death. Following this award, he holds 11,389 RSUs, stock options over 8,160 shares at an exercise price of $4.9600 that vest over three years, and common stock holdings of 13,113 shares directly plus 1,740 shares indirectly through the Lin Family Trust. These amounts reflect a 1-for-25 reverse stock split effective December 17, 2025, and were not reported as made under a Rule 10b5-1 trading plan.
Processa Pharmaceuticals, Inc. reported that Chief Administrative Officer Wendy Guy received a grant of 9,450 Restricted Stock Units on 2026-07-26, each representing one share of common stock. These RSUs vested on grant but will be delivered in shares at the earlier of termination, six months after grant, a change of control, or death.
After this award, Guy holds 11,669 RSUs directly, stock options for 6,000 shares at an exercise price of $4.9600 vesting over three years, 14,394 shares of common stock directly, and 333 shares indirectly through CorLyst, LLC.